Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high‐risk osteosarcoma patients
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A phase 2 trial was carried out to assess the antineoplastic activity of 2 courses of cyclophosphamide‐etoposide in relapsed osteosarcoma patients. METHODS: Twenty‐six relapsed osteosarcoma patients with a median age of 18.5 years (8.3‐47.1) were enrolled. Seven patients were in first relapse (27%), 11 in second relapse (42%), 7 in third relapse (27%), and 1 in fourth relapse (4%). Eighteen patients had bone metastasis at study entry (69%). Cyclophosphamide was given at 4 g/m 2 on Day 1 followed by etoposide at 200 mg/m 2 on Days 2, 3, and 4. Second cyclophosphamide and etoposide was planned at 21 days to 28 days from the previous one. The primary endpoint of the study was the clinical benefit at 4 months measured as progression‐free survival. RESULTS: Progression‐free survival at 4 months was 42%. Five patients achieved responses (19%), 9 patients had stable disease (35%), and 12 had tumor progression (46%). Overall survival (OS) at 1 year was 50%. The only grade 4 extrahematological toxicities were fever (5%), acute bronchospasm (4%) and stomatitis (18%). Six patients (23%) underwent radical surgery after cyclophosphamide and etoposide ×2. CONCLUSIONS: Cyclophosphamide and etoposide ×2 may arrest osteosarcoma progression in a significant number of patients (54%). Osteosarcoma progression arrest after cyclophosphamide and etoposide ×2 translates in a better OS. Cyclophosphamide and etoposide ×2 had good tolerability and the toxicity was time‐limited and resolved in all cases. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival
Ferrari, S., Briccoli, A., Mercuri, M., Bertoni, F., Picci, P., Tienghi, A., Del Prever, A. B., Fagioli, F., Comandone, A., & Bacci, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.141 · Cited by 316 · cited 2×
“Best response Complete response 2 (8) Partial response 3 (11) Stable disease 9 (35) Progressive disease 12 (46)”
BackgroundSelf-citationMeyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., & Healey, J. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2452 · Cited by 294
Gentet, J.-C., Brunat-Mentigny, M., Demaille, M. C., Pein, F., Avet-Loiseau, H., Berger, C., De Lumley, L., Pacquement, H., Schmitt, C., Sariban, E., et al. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00439-x · Cited by 86
Treatment of Refractory Osteosarcoma With Fractionated Cyclophosphamide and Etoposide
Rodríguez-Galindo, C., Daw, N. C., Kaste, S. C., Meyer, W. H., Dome, J. S., Pappo, A. S., Rao, B. N., & Pratt, C. B. (2002) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200205000-00006 · Cited by 40
Cited by
Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Self-citationGrignani, G., Palmerini, E., Ferraresi, V., D'Ambrosio, L., Bertulli, R., Asaftei, S. D., Tamburini, A., Pignochino, Y., Sangiolo, D., Marchesi, E., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71136-2 · Cited by 340
Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E., Delcambre, C., Kalbacher, E., Italiano, A., Collard, O., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30742-3 · Cited by 331
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 283
Metadata
- Authors
- Massimo, B., Giovanni, G., Stefano, F., Eleonora, B., Adalberto, B. D. P., Sandra, A., Francesco, S., Massimo, A., & Franca, F.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-05-18
- Volume
- 115
- Issue
- 13
- Pages
- 2980-2987
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1975253840
- Cited by
- 61
- References
- 4
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.